NY-ESO-1 specific antibodies are frequently detected in hight-risk myeloma.

被引：0
|
作者：
van Rhee, F
Szmania, SM
Pomtree, M
Zhan, F
Moreno, A
Rosen, N
Fox, M
Barlogie, B
Shaughnessy, J
Batchu, R
Tricot, GJ
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2464
引用
收藏
页码：676A / 676A
页数：1
相关论文
共 50 条
  • [31] HUMAN CLEC9A ANTIBODIES DELIVER NY-ESO-1 ANTIGEN TO CD141+DENDRITIC CELLS TO ACTIVATE NAIVE AND MEMORY NY-ESO-1-SPECIFIC CD8+T CELLS
    Masterman, Kelly-Anne
    Haigh, Oscar
    Tullett, Kirsteen
    Leal-Rojas, Ingrid
    Walpole, Carina
    Pearson, Frances
    Cebon, Jonathon
    Schmidt, Christopher
    O'Brien, Liam
    Rosendahl, Nikita
    Daraj, Ghazal
    Caminschi, Irina
    Gschweng, Eric
    Hollis, Roger
    Kohn, Donald
    Lahoud, Mireille
    Radford, Kristen
    Radford, Kristen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A368 - A368
  • [32] NY-ESO-1-Specific CD8 T Cell Response in NY-ESO-1 Seropositive Metastatic Melanoma Patients Treated with Ipilimumab Correlates with Clinical Benefit
    Yuan, Jianda
    Gnjatic, Sacha
    Adamow, Matthew
    Ginsberg, Brian
    Rasalan, Teresa S.
    Ritter, Erika
    Gallardo, Humilidad F.
    Xu, Yinyan
    Pogoriler, Evelina
    Panageas, Katherine S.
    Yang, Arvin
    Terzulli, Stephanie
    Ritter, Gerd
    Old, Lloyd J.
    Allison, James P.
    Wolchok, Jedd D.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 913 - 914
  • [33] Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
    Oka, M.
    Kurose, K.
    Sakaeda, K.
    Fukuda, M.
    Sakai, Y.
    Atarashi, Y.
    Shimizu, K.
    Masuda, T.
    Nakatomi, K.
    Kawase, S.
    Suetsugu, T.
    Mizuno, K.
    Takemoto, S.
    Yamaguchi, H.
    Inoue, H.
    Hattori, N.
    Nakata, M.
    Mukae, H.
    Oga, T.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S370 - S370
  • [34] NY-ESO-1 Expression Is Highly Sensitive and Specific in the Diagnosis of Myxoid Liposarcoma Using Cytology Cell Blocks
    Smith, Stephen M.
    Jin, Ming
    Wakely, Paul E.
    Iwenofu, O. Hans
    MODERN PATHOLOGY, 2017, 30 : 118A - 118A
  • [35] NY-ESO-1 Expression Is Highly Sensitive and Specific in the Diagnosis of Myxoid Liposarcoma Using Cytology Cell Blocks
    Smith, Stephen M.
    Jin, Ming
    Wakely, Paul E.
    Iwenofu, O. Hans
    LABORATORY INVESTIGATION, 2017, 97 : 118A - 118A
  • [36] Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
    Lattanzi, Michael
    Han, Joseph
    Moran, Una
    Utter, Kierstin
    Tchack, Jeremy
    Sabado, Rachel Lubong
    Berman, Russell
    Shapiro, Richard
    Huang, Hsin-Hui
    Osman, Iman
    Bhardwaj, Nina
    Pavlick, Anna C.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [37] NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
    van Rhee, F
    Szmania, SM
    Zhan, FH
    Gupta, SK
    Pomtree, M
    Lin, P
    Batchu, RB
    Moreno, A
    Spagnoli, G
    Shaughnessy, J
    Tricot, G
    BLOOD, 2005, 105 (10) : 3939 - 3944
  • [38] NY-ESO-1 Is a Sensitive and Specific Marker for Myxoid and Round Cell Liposarcomas among Other Mesenchymal Myxoid Neoplasms
    Hemminger, J. A.
    Toland, A. E.
    Iwenofu, O. H.
    LABORATORY INVESTIGATION, 2013, 93 : 13A - 13A
  • [39] Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients
    Weide, B.
    Zelba, H.
    Derhovanessian, E.
    Pflugfelder, A.
    Schadendorf, D.
    de Vries, J.
    Maio, M.
    Garbe, C.
    Pawelec, G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (09): : 781 - 782
  • [40] NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC
    Takeoka, Tomohira
    Nagase, Hirotsugu
    Kurose, Koji
    Ohue, Yoshihiro
    Yamasaki, Makoto
    Takiguchi, Shuji
    Sato, Eiichi
    Isobe, Midori
    Kanazawa, Takayuki
    Matsumoto, Mitsunobu
    Iwahori, Kota
    Kawashima, Atsunari
    Morimoto-Okazawa, Akiko
    Nishikawa, Hiroyoshi
    Oka, Mikio
    Pan, Linda
    Venhaus, Ralph
    Nakayama, Eiichi
    Mori, Masaki
    Doki, Yuichiro
    Wada, Hisashi
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (04) : 140 - 147
12345